Biodesix, Inc.

NASDAQ:BDSX

Medical - Diagnostics & Research

Healthcare
$8.40 +13.40%

+$2.04 today

Market cap
$68.38M
Beta
0.59
P/E (TTM)
-5.2
EPS (TTM)
-$3.31
52W Low $5.00High $20.21

Volume 0.17M

Average 0.06M

BDSX Interest Expense

Cost of servicing the company's debt during the period.

Biodesix, Inc.NASDAQ: BDSX

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense growth accelerates

Q1 FY2026 interest expense of $1.98M rose 17.3% year over year, ahead of the +8.0% change in trailing-twelve-month interest expense. Sequentially, it fell 4.0% from the prior quarter. Over 3 fiscal years it compounded at -1.5% a year.

Context

  • Interest expense amounted to 8.7% of revenue in FY2025, down 2.9 pp from a year earlier.
  • Interest expense increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +17.3% holds above the trailing-twelve-month pace of +8.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.98M-4.0% QoQ
Last fiscal yearDec 2025
$7.72M-6.6% YoY
LTMMar 2026
$8.01M+8.0% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+17.3%——
1 year-6.6%——
3-year CAGR-1.5%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
7.72M USD
Year-over-year change
-6.6%
4-year CAGR
+14.4%

Interest Expense vs competitors

How BDSX compares with its peers on the latest reported figures

  • BDSX's LTM Mar 2026 interest expense of $8.01M is the highest of the 5 companies compared; the peer median is $4K.
  • Its year-over-year change of +8.0% is the 2nd highest of 3, against a peer median of -23.4%.
  • Interest expense amounts to 8.3% of revenue for BDSX, versus a peer median of 0.0%.
BDSX Competitors Peer median
Interest Expense for BDSX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BDSXBiodesix, Inc.LTM Mar 2026$8.01M +8.0%-1.5%8.3%
PDSBPDS Biotechnology CorporationLTM Mar 2026$5.42M +22.4%+59.4%—
OKUROnKure Therapeutics, Inc.LTM Mar 2026$8K -69.2%——
XLOXilio Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
INMBINmune Bio, Inc.LTM Mar 2026$0 ———
Peer median (excluding BDSX) $4K-23.4%+59.4%0.0%

Competitors are the stored peer set for BDSX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue54.51M38.21M49.09M71.32M88.5M
Cost of Revenue30.52M14.15M13.01M15.57M16.72M
Gross Profit23.99M24.06M36.08M55.75M71.78M
Gross Margin44.0%63.0%73.5%78.2%81.1%
Research & Development12.79M13.1M9.99M9.56M12M
Selling, General & Admin50.52M61.46M67.39M80.45M87.55M
Operating Expenses64.93M74.65M77.42M90.25M99.55M
Depreciation & Amortization3.18M5.84M5.51M5.46M5.6M
EBITDA(35.47M)(51.53M)(37.1M)(29.22M)(21.95M)
EBITDA Margin-65.1%-134.9%-75.6%-41.0%-24.8%
Operating Income(40.94M)(50.59M)(41.34M)(34.5M)(27.77M)
Operating Margin-75.1%-132.4%-84.2%-48.4%-31.4%
Interest Income00000
Interest Expense4.51M8.07M9.54M8.26M7.72M
Other Income / Expenses(2.22M)(14.86M)(10.8M)(8.43M)(7.5M)
Income Before Tax(43.16M)(65.45M)(52.15M)(42.93M)(35.27M)
Pre-Tax Margin-79.2%-171.3%-106.2%-60.2%-39.8%
Income Tax Expense00000
Net Income(43.16M)(65.45M)(52.15M)(42.93M)(35.27M)
Net Margin-79.2%-171.3%-106.2%-60.2%-39.8%
EPS (Basic)(31.60)(31.00)(12.80)(6.60)(4.67)
EPS (Diluted)(31.60)(31.00)(12.80)(6.60)(4.67)
Weighted Avg Shares1.37M2.11M4.11M6.48M7.55M
Weighted Avg Shares (Diluted)1.37M2.11M4.11M6.48M7.55M

Biodesix, Inc.

NASDAQ:BDSX

Intrinsic Alpha fair value

Locked

Current Price

$8.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.